Boomtown

[Robertscott]

$TXTM BOCA RATON, FL--(Marketwired - Sep 13, 2017) - Protext Pharma, Inc. ( OTC PINK : TXTM ) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical botanical medicines that are formulated with highly-bioavailable plant extracts, today announced that, following extensive investigations with scientists at a leading United States diabetic research institute, the company is modifying its forthcoming diabetes study protocols. The studies will focus on establishing an effective therapeutic dosage point for Phytofare® catechin complex as a first line protocol for Type 2 diabetes while also investigating whether Phytofare® catechins can prevent or manage Type 1 diabetes. The Company's near-term goal is to market Phytofare®, which has been clinically proven to have superior bioavailability, as a primary therapy with specific structure-function claims based on forthcoming study results.

https://finance.yahoo.com/news/protext-pharma-conduct-clinical-trial-141658561.html